Literature DB >> 30518787

Low-dose IL-2 therapy for autoimmune diseases.

Joanna Collison1.   

Abstract

Entities:  

Year:  2019        PMID: 30518787     DOI: 10.1038/s41584-018-0142-1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Authors:  Michelle Rosenzwajg; Roberta Lorenzon; Patrice Cacoub; Hang Phuong Pham; Fabien Pitoiset; Karim El Soufi; Claire RIbet; Claude Bernard; Selim Aractingi; Beatrice Banneville; Laurent Beaugerie; Francis Berenbaum; Julien Champey; Olivier Chazouilleres; Christophe Corpechot; Bruno Fautrel; Arsène Mekinian; Elodie Regnier; David Saadoun; Joe-Elie Salem; Jérémie Sellam; Philippe Seksik; Anne Daguenel-Nguyen; Valérie Doppler; Jéremie Mariau; Eric Vicaut; David Klatzmann
Journal:  Ann Rheum Dis       Date:  2018-11-24       Impact factor: 19.103

  1 in total
  3 in total

1.  Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.

Authors:  Maryam Tahvildari; Reza Dana
Journal:  J Immunol       Date:  2019-12-01       Impact factor: 5.422

Review 2.  Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

Authors:  Zhussipbek Mukhatayev; Yekaterina O Ostapchuk; Deyu Fang; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2021-01-18       Impact factor: 17.390

Review 3.  The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity.

Authors:  Yun-Shiuan Olivia Hsu; Kun-Lin Lu; Yun Fu; Chuang-Wei Wang; Chun-Wei Lu; Yu-Fen Lin; Wen-Cheng Chang; Kun-Yun Yeh; Shuen-Iu Hung; Wen-Hung Chung; Chun-Bing Chen
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.